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ABSTRACT: The exploitation of curcumin for oral disease
treatment is limited by its low solubility, poor bioavailability,
and low stability. Surface-functionalized poly-lactic-co-glycolic
acid (PLGA) nanoparticles (NPs) have shown promising
results to ameliorate selective delivery of drugs to the gastro-
intestinal tract. In this study, curcumin-loaded PLGA NPs (C-
PLGA NPs) of about 200 nm were surface-coated with
chitosan (CS) for gastro-intestinal mucosa adhesion, wheat
germ agglutinin (WGA) for colon targeting or GE11 peptide
for tumor colon targeting. Spectrometric and zeta potential
analyses conﬁrmed the successful functionalization of the C-
PLGA NPs. Real-time label-free assessment of the cell
membrane-NP interactions and NP cell uptake were
performed by quartz crystal microbalance coupled with supported lipid bilayers and by surface plasmon resonance coupled
with living cells. The study showed that CS-coated C-PLGA NPs interact with cells by the electrostatic mechanism, while both
WGA- and GE11-coated C-PLGA NPs interact and are taken up by cells by speciﬁc active mechanisms. In vitro cell uptake
studies corroborated the real-time label-free assessment by yielding a curcumin cell uptake of 7.3 ± 0.3, 13.5 ± 1.0, 27.3 ± 4.9,
and 26.0 ± 1.3 μg per 104 HT-29 cells for noncoated, CS-, WGA-, and GE11-coated C-PLGA NPs, respectively. Finally,
preliminary in vivo studies showed that the WGA-coated C-PLGA NPs eﬃciently accumulate in the colon after oral
administration to healthy Balb/c mice. In summary, the WGA- and GE11-coated C-PLGA NPs displayed high potential for
application as active targeted carriers for anticancer drug delivery to the colon.
1. INTRODUCTION
Curcumin is a natural product with a wide range of
pharmacological activities, including anti-inﬂammatory,1,2
antioxidant,3,4 and antimicrobial eﬀects.5,6 The most attractive
property of curcumin is, however, its ability to inhibit cell
proliferation and induce apoptotic cell death of a wide variety
of tumor cells.7,8 Unfortunately, the exploitation of curcumin
as anticancer agent is hampered by its low solubility and rapid
decomposition in aqueous medium, photo-instability, and poor
bioavailability.
Nanoparticles (NPs) have widely been studied as drug
carriers for anticancer drug delivery9,10 because they can
protect drugs from harsh environments and enable sustained
drug release or tumor targeting. The surface properties of NPs,
namely charge, hydrophilic/lipophilic features, and targeting
agents, dictate their interaction with cells and consequently
their bioselectivity. For example, negatively charged NPs are
poorly taken up by cells compared to positively charged
NPs.11,12 On the other hand, surface-coated NPs with targeting
moieties have been developed to enhance the cell selectivity
and the intracellular delivery of drugs with a narrow
therapeutic window and low cell membrane permeability.13
Poly-lactic-co-glycolic acid (PLGA) NPs decorated with
mucoadhesive materials, including polymers, lectins,14 and
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peptides,15 have been developed for oral administration to
selectively deliver drugs to the gastro-intestinal tract (GIT).
Chitosan (CS) coating can endow NPs with mucoadhesive
properties and enhanced transmucosal penetration.16−18 CS
can also promote coulombic interactions with negatively
charged cancer cells, which translocate negatively charged
constituents of the inner layer of the cell membrane (e.g.,
phosphatidylserine, anionic phospholipids, glycoproteins, and
proteoglycans) to the cell surfaces.19
Small molecules and macromolecules have also been
exploited to generate targeted NPs with speciﬁc mucoadhe-
sivity or cell surface selectivity. Lectins, the second generation
mucoadhesives,20 enable site-speciﬁc targeting to mucosal cells
through noncovalent carbohydrate residue binding.21,22 For
example, wheat germ agglutinin (WGA) is a dietary lectin that
recognizes N-acetyl-D-glucosamine and sialic acid exposed on
the cell membranes of human colonocytes, colon cancer cells,
and prostate cancer cells.23 EGF analogue peptides such as
GE11,24 a peptide devoid of bioactivity, have been used to
produce drug delivery systems that selectively target the
epidermal growth factor receptor overexpressed on tumor
cells,25,26 including gastric, colorectal, oesophageal, nonsmall
cell lung cancer, and ovarian cancer cells.27,28
The biopharmaceutical and pharmacokinetic (PK) charac-
terization of tailored NPs is a critical step in the development
of eﬃcient drug delivery systems. Real-time label-free in vitro
analytical techniques can provide complementary information
to conventional label-based biochemical and in vitro cell
culture assays. This can improve the cost- and time
eﬀectiveness of the development of NPs by providing new
complementary tools for selecting candidates with the
biopharmaceutical requisites for further in vivo testing, as
well as for building a better comprehension of their PK
behavior.
Quartz crystal microbalance (QCM) combined with solid
supported lipid bilayers (SLBs)29,30 and living cell sensing with
surface plasmon resonance (SPR)31−35 are two real-time label-
free in vitro surface-sensitive technologies providing rapid
information on interfacial processes while obviating the need
for additional labeling processes. Although, SPR and QCM
have been used since the 1990s for biomolecular interaction
studies, they are still unexplored for research and development
of pharmaceutical nanosystems. The QCM is a mechanical
measuring technique providing nanoscale sensitivity for mass
and viscoelasticity measurements by utilizing the changes in
resonant frequency and dissipation of quartz crystal resonators
upon the deposition of mass on the sensor surface. The SPR
technique, on the other hand, relies on the SPR phenomena
and measures the changes in the refractive index in the close
vicinity of SPR metal sensors upon mass deposition on the
sensor surfaces.
The main objective of the present study was to investigate
the targeting of curcumin-loaded PLGA (C-PLGA) NPs to
human colorectal adenocarcinoma cells (HT-29). Accordingly,
C-PLGA NPs were surface coated with CS, WGA, and GE11
in order to improve the cell uptake of the NPs and
consequently ameliorate the delivery of curcumin to the
cells. The behavior of these three platforms was investigated
with new label-free approaches and traditional methods. Real-
time label-free QCM and SPR measurements were used to
assess the cell membrane surface interactions and targeting
capability of noncoated and coated C-PLGA NPs to HT-29
cells. Complementary physicochemical characterization of
noncoated and coated C-PLGA NPs were performed through
particle size, zeta potential, drug entrapment eﬃciency, and in
vitro drug release kinetics measurements. Traditional in vitro
cell studies were also performed to determine in vitro cell
uptake of curcumin and cell viability of HT-29 cells. Finally, a
preliminary in vivo study with healthy Balb/c mice was
performed to evaluate the accumulation of noncoated and
targeted C-PLGA NPs in the colon after oral administration.
2. EXPERIMENTAL SECTION
2.1. Materials. Curcumin was purchased from Cayman
chemical company (China, purity 91%). Acid-terminated
poly(D,L-lactide-co-glycolide) (PLGA, 50:50, 7−17 kDa MW,
Resomer RG 502H), polyvinyl alcohol (PVA, 31−50 kDa
MW; 87−89% hydrolyzed), chitosan (CS, medium MW),
ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetra-acetic
acid (EGTA, purity ≥ 97%), 3-[(3-cholamidopropyl)-
dimethylammonio]-1-propanesulfonate (CHAPS, purity ≥
98%), Triton X-100 (purity for molecular biology), N-
hydroxysuccinimide (NHS, purity 98%), mannitol (purity ≥
98%), sodium taurocholate (purity ≥ 95%), trypan blue
solution (purity suitable for cell culture), and the MTT-based
in vitro toxicology assay kit were purchased from Sigma-
Aldrich (Finland). WGA was purchased from Vector
laboratories, Inc. (USA). Mucin extracted from porcine
stomach (Type III) and pepsin from porcine gastric mucosa
were purchased from LEE Biosolutions (USA). Pectinase from
Aspergillus niger was purchased from Sigma-Aldrich Life
Science (Denmark). N-(3-Dimethylaminopropyl)-N-ethylcar-
bodiimide hydrochloride (EDC, purity ≥ 99%) was purchased
from Fluka Analytical (Japan). Cyanine 5.5 NHS ester (Cy5.5-
NHS, purity 95%) was purchased from Lumiprobe GmbH
(Germany). The GE11-PEG-NH2 and the Cy5.5-PEG-NH2
were synthesized according to the protocols set up by Balasso
et al. to conjugate the peptide PreS1 and the ﬂuorescent probe
rhodamine, respectively, to NH2-PEG-NH2.
36
L-α-Phosphati-
dylcholine (eggPC, purity 95%), 1,2-dioleoyl-sn-glycero-3-
[phospho-L-serine] (sodium salt) (DOPS, purity > 99%),
and 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC,
purity > 99%) were purchased from Avanti Polar Lipids
(USA). Dulbecco’s Modiﬁed Eagle Medium (DMEM),
Dulbecco phosphate-buﬀered saline (DPBS), McCoy’s 5A
medium, OPTI-MED-reduced serum medium, fetal bovine
serum (FBS), TrypLE express, and the μ-b bicinchoninic acid
protein assay kit (Pierce μ-BCA kit) were purchased from
Thermo Fischer Scientiﬁc (Finland). Hellmanex II was
obtained from Hellma GmbH (Germany). High purity water
(18.2 MΩ cm) from a Millipore Milli-Q system (USA) was
used for the preparation of all buﬀer and water-based solutions.
All other salts and solvents were from Sigma-Aldrich (Finland,
purity of at least Reagent grade).
2.2. Preparation and Characterization of the For-
mulations. 2.2.1. Preparation of the Curcumin-Loaded
PLGA NPs (C-PLGA NPs). Noncoated curcumin-loaded PLGA
NPs (C-PLGA NPs) were prepared as described previously.37
Brieﬂy, 176 mg of PLGA was dissolved in 5 mL of
dichloromethane (DCM) and 16.6 mg of curcumin was
added to the solution. The organic curcumin/PLGA solution
was rapidly dropped into a glass tube containing 10 mL of 2%
PVA in high purity water under vortexing. The mixture was
vortexed for further 10 s at a high setting and sonicated for 7
min at 40% amplitude in an ice-water bath by using a probe
sonicator (Vibra-Cell VCX 750 sonicator, Sonics & Materials
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Inc., Newtown, CT, USA). The resulting ﬁne O/W emulsion
was immediately poured into 30 mL of 0.5% PVA in high
purity water under rapid stirring with a magnetic stirrer. DCM
was then evaporated under magnetic stirring at 800 rpm for 3 h
and the NPs were collected by centrifugation at 48 000g for 15
min and washed 3 times with high purity water. The
supernatant was collected, desiccated under vacuum, and the
encapsulation eﬃciency of curcumin was evaluated as
described in Section 2.2.6.
2.2.2. Chitosan Functionalization of C-PLGA NPs. C-
PLGA NPs coated with chitosan (CS-C-PLGA NPs) were
prepared as described above, provided that 5 mL of CS
solutions (0.25, 0.50, or 1% w/v) in 1% glacial acetic acid were
added to 5 mL PVA aqueous solution prior the emulsiﬁcation
with the curcumin/PLGA organic solution.17
2.2.3. Preparation of Lectin or Peptide Ligand-Coated C-
PLGA NPs. C-PLGA NPs were surface-coated with WGA lectin
or GE11 peptide according to a two-step EDC/NHS
method.38,39 Brieﬂy, 5 mL aliquots of noncoated C-PLGA
NP suspensions in high purity water were washed with 20 mL
0.1 M MES buﬀer, pH 5.8, and then the noncoated C-PLGA
NPs were separated by centrifugation at 15 000g. The
noncoated C-PLGA NPs were incubated with approximately
0.1 M EDC and 0.15 M NHS in 0.1 M MES buﬀer, pH 5.8, for
1 h at room temperature (RT). The EDC excess was quenched
by washing three times with 20 mL of 20 mM phosphate, 0.15
M (PBS), pH 7.4. The activated C-PLGA NPs were
resuspended in 5 mL PBS, pH 7.4, and added of 1 mL of 1
mg/mL WGA lectin or GE11 peptide in the same buﬀer and
the suspension was maintained overnight under gentle
agitation. The resulting WGA-coated NPs (WGA-C-PLGA
NPs) and GE11-coated NPs (GE11-C-PLGA NPs) were
added of 1 mL of 50 mM glycine. After 1 h, the WGA-C-PLGA
and GE11-C-PLGA NPs were separated by centrifugation,
washed twice with PBS, pH 7.4, and ﬁnally collected by
centrifugation.
2.2.4. Determination of the Amount of Bound WGA and
GE11 to C-PLGA NPs. A water-based system comprised 2 mL
DMSO and 10 mL of 0.05 N NaOH containing 0.5% SDS was
used to dissolve the WGA-C-PLGA and GE11-C-PLGA NPs
for determining the amount of ligands conjugated on the C-
PLGA NPs. The amount of WGA lectin or GE11 peptide
ligand in the dissolved NP solutions was quantiﬁed by
colorimetric determination of the WGA lectin/GE11 peptide
content by using a μ-BCA protein assay. The WGA lectin or
GE11 peptide conjugation density and eﬃciency was
calculated from the following equations
CD
amount of ligand added amount of unconjugated ligand
total amount of nanoparticles
= −
i
k
jjjjj
y
{
zzzzz
(1)
CE
amount of ligand added amount of unconjugated ligand
amount of ligand added
100%
= −
×
i
k
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y
{
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(2)
2.2.5. Physicochemical Characterization of Noncoated
and Coated C-PLGA NPs. The particle size, polydispersity
index (PDI), and zeta potential of noncoated and chitosan,
WGA-, and GE11-coated C-PLGA NPs were measured at RT
by using a ZetaSizer Nano ZS instrument (Malvern Instru-
ments Ltd, Worcestershire, UK) after NP dispersion in high
purity water. Morphological analyses were performed with a
JEOL 1200 EX II transmission electron microscope (JEOL
Ltd., Tokyo, Japan).
2.2.6. Encapsulation Eﬃciency of Curcumin in Noncoated
and Coated C-PLGA NPs. The encapsulation eﬃciency of
curcumin in noncoated and chitosan, WGA-and GE11-coated
C-PLGA NPs was determined by dissolving the NPs in
acetonitrile and determining the amount of curcumin by
ultraperformance liquid chromatography (AcquityTM, Waters
Corp., Milford, Massachusetts, USA) at λmax = 426 nm
(according to the procedure reported in the literature,40 2011),
with minor changes.37 The drug encapsulation eﬃciency (EE
%) for each NP was calculated by using the following equation:
% EE
amount of encapsulated curcumin
total amount of curcumin
100= ×i
k
jjjj
y
{
zzzz (3)
2.2.7. In Vitro Curcumin Release from Noncoated and
Coated C-PLGA NPs. The in vitro release of curcumin from
noncoated and chitosan, WGA- and GE11-coated C-PLGA
NPs was determined by the dialysis bag method reported by
Zanotto-Filho et al.,41 with slight modiﬁcations. A three-stage
approach with three diﬀerent pH release media was used in
order to follow the recommendations on methods for dosage
form testing by US Pharmacopeia 36,42 as described earlier.37
The media and time intervals used for the three diﬀerent stages
were the following: simulated gastric ﬂuid (SGF; 0.2% NaCl,
0.2% pepsin, 0.7% hydrochloric acid, pH 1.2) between 1 and 2
h, simulated intestinal ﬂuid (SIF; 0.68% KH2PO4, 3 mM
sodium taurocholate, pH 6.8) between 3 and 5 h, and
simulated colonic ﬂuid (SCF; PBS, pH 7.4) between 6 and 24
h. The NP suspensions were placed into dialysis bags with a
molecular cutoﬀ of 12−14 kDa and dialyzed in the dark against
150 mL of the corresponding media for each time interval.
Samples from the solution in the external buﬀer were taken at
scheduled times and analyzed by ultraperformance liquid
chromatography (AcquityTM, Waters Corp., Milford, Massa-
chusetts, USA) at λmax = 426 nm, as described earlier.
37
2.2.8. In Vitro Stability of Noncoated and Coated C-PLGA
NPs. The stability of noncoated and chitosan, WGA-, and
GE11-coated C-PLGA NPs in high purity water was assessed
at two diﬀerent temperatures (4 °C and RT) for up to four
months. Stability of NPs in SGF, SIF, and SCF at 37 °C was
assessed by incubation of 1 mg of NPs in 1 mL of the
corresponding ﬂuids for appropriate times for simulating GI-
tract residence times. At scheduled time, samples were taken
and analyzed by ZetaSizer Nano ZS (Malvern Instruments Ltd,
Worcestershire, UK). The experimental data were elaborated
according to the method used previously.37
2.2.9. In Vitro Mucin Adsorption to Noncoated and
Coated C-PLGA NPs. Adsorption of pig mucin (PM) on the
surface of noncoated and chitosan, WGA-, and GE11-coated
C-PLGA NPs was determined by slightly modifying the
method reported by Yin et al.43 Brieﬂy, 1 mL of mucin
suspension (1 mg/mL) in PBS with pH 7.4 was stirred with 1
mL of each C-PLGA NP formulation for 2 h at 37 °C. Then,
the suspensions were centrifuged at 25 000g for 1 h. The
amount of free PM in the supernatant was determined by
measuring the absorbance value at 260 nm by using a UV
spectrophotometer (UV Visible Spectrophotometer, Cary 100
Conc, Australia). The amount of adsorbed PM was calculated
by using a standard curve measured for known amounts of PM
in PBS. The calibration curve for mucin in PBS was
determined with a series of mucin standard solutions with
concentrations of 30, 60, 125, 250, 500, 750, and 850 μg/mL.
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The PM binding eﬃciency of the diﬀerent C-PLGA NPs was
calculated from the following equation
C C
C
PM binding efficiency % 0 s
0
= −
i
k
jjjjj
y
{
zzzzz (4)
where C0 is the initial concentration of PM used for incubation
and Cs is the concentration of free PM determined in the
supernatant.
2.3. QCM Studies. 2.3.1. QCM Sensor Preparation. The
silica-coated QCM sensor crystals (Biolin Scientiﬁc, Q-Sense,
Gothenburg, Sweden) was cleaned by boiling them in a
cleaning solution (water/hydrogen peroxide/ammonium
hydroxide; 5/1/1, v/v/v) for 5 min followed by rinsing with
copious amounts of ion-exchanged water and ﬁnally blow-
drying with nitrogen. Prior and after each QCM measurement,
the SiO2-coated QCM sensor crystal was cleaned in situ by
ﬂushing the ﬂow channel with sequential 5 min injections of 20
mM CHAPS, 2% Hellmanex II, 95% ethanol, and high purity
water.
2.3.2. Preparation of EggPC and DOPC/DOPS Cell Model
Membranes on QCM Sensors. Vesicle rupture of EggPC or
DOPC/DOPS (75/25 mol %) vesicles was used to prepare
SLBs on the silica-coated QCM sensor crystals as simple cell
model membranes. Phospholipids were dissolved separately in
a deﬁned amount in chloroform and stored at −20 °C until
used for preparation of vesicles for SLB formation. Vesicles
were prepared by evaporating the solvent from EggPC or a
mixture of DOPC/DOPS in chloroform to dryness under a
stream of nitrogen. The formed lipid ﬁlms were then hydrated
with a 20 mM Hepes/150 mM NaCl buﬀer solution with pH
7.4 at RT by vortexing to obtain vesicle suspensions with a
total lipid content of 10 mg/mL. The vesicle suspensions were
sonicated by a tip sonicator (Vibra-Cell VCX 750 sonicator,
Sonics & Materials Inc., Newtown, CT, USA) until clear
solutions were obtained. The vesicle solutions were then
centrifuged for 1 min at 15 000g to remove titanium particles.
The particle size, PDI index, and ZP of the vesicle solutions
were determined by using a ZetaSizer Nano ZS instrument
(Malvern Instruments Ltd, Worcestershire, UK). The vesicle
solutions were stored at 4 °C and used within two weeks. Just
before preparing the SLBs for QCM measurements, the vesicle
solutions were diluted with a 20 mM HEPES/150 mM NaCl/5
mM CaCl2 buﬀer solution with pH 7.4 to a total lipid content
of 0.1 mg/mL.
2.3.3. HT-29 Cell Membrane Extraction and Use for SLB
Formation on QCM Sensors. HT-29 cell pellets (cells cultured
as described in Section 2.5.1.) collected from 8 cell culture
ﬂasks were suspended in 10 mL of a harvest buﬀer (50 mM
Tris-HCl, 300 mM mannitol, pH 7). The obtained cell
suspension was centrifuged at 800g for 5 min at 4 °C and the
supernatant was thrown away. This step was repeated twice.
The residue was further suspended in 10 mL of a membrane
buﬀer (50 mM Tris-HCl, 50 mM mannitol, and 2 mM EGTA,
pH 7). The obtained cell suspension was transferred into a cell
homogenizer and homogenized by 40 strokes followed by
incubation on ice for 1 h. The cells homogenized were
transferred into a Falcon tube and centrifuged at 800g for 10
min at 4 °C. The supernatant from this step was taken and
centrifuged at 15 000g for 1 h at 4 °C. The supernatant was
again taken and further centrifuged at 100 000g for 1.15 h at 4
°C. Finally, the supernatant was removed and the pellet formed
by the cell membrane extract was weighed and stored at −75
°C until used. Just before use in QCM measurements, the HT-
29 cell membrane extract pellet was suspended in a 20 mM
Hepes/150 mM NaCl buﬀer solution with pH 7.4 to reach a
concentration of 10 mg/mL of the membrane extract. This
suspension was further mixed by using a 27G needle by ﬁlling
and emptying the syringe with the whole suspension.
Hereafter, the suspension was sonicated for 20 min until the
solution no longer appeared cloudy and used immediately. A
qualitative test for the presence of proteins in the extracted cell
membrane suspension was performed using a BCA Protein
Assay Reagent kit, which veriﬁed that the cell membrane
extract contained a substantial amount of protein. The HT-29
cell membrane extract was diluted as such or in a mixture with
diﬀerent mass ratios of EggPC vesicles (1/1, 1/1.5 1/2, and 1/
2.5, respectively) in order to ﬁnd the optimized cell membrane
extract/EggPC ratio for SLB formation. The HT-29 cell
membrane extract and cell membrane extract/EggPC mixtures
were diluted with a 20 mM HEPES/150 mM NaCl/5 mM
CaCl2 buﬀer solution with pH 7.4 to a cell membrane extract/
lipid concentration of 0.14 mg/mL just before performing the
QCM measurements for verifying SLB formation.
2.3.4. QCM Measurements. QCM measurements were
performed at 20 °C by using an impedance-based QCM
instrument (QCM-Z500, KSV Instruments, Helsinki, Finland).
Measurement data for frequency ( f) and dissipation (D) were
acquired at the fundamental frequency (5 MHz) and several
overtone frequencies (15, 25, 35, 45, and 55 MHz). The
interaction of the noncoated and chitosan, WGA- and GE11-
coated C-PLGA NPs with DOPC/DOPS and the HT-29 cell
membrane extract/EggPC SLBs were performed by monitor-
ing QCM signal responses for a ﬁxed time of 30 min when 1
mg/mL of the NPs were injected into the QCM ﬂow channel.
The ﬂow rate during the QCM interaction measurements was
kept constant at 50 μL/min, and a 20 mM HEPES/150 mM
NaCl buﬀer solution with pH 7.4 was used as the running
buﬀer during the measurements. The frequency and
dissipation changes reported for the QCM measurements are
the normalized signal changes for the 3rd overtone frequency,
if not otherwise stated.
2.4. SPR Studies. 2.4.1. Immobilization of Cells on SPR
Sensors. Gold-coated SPR sensor slides (Bionavis Ltd.,
Tampere, Finland) were cleaned by boiling in a solution of
high purity water, 30% hydrogen peroxide, and 30%
ammonium hydroxide solution (5/1/1; v/v/v) for 5 min.
After boiling, the sensor slides were rinsed thoroughly with
high purity water and dried by aspirating them. The SPR
sensors were hereafter autoclaved before cell immobilization.
The immobilization of HT-29 cells (cultured as described in
Section 2.5.1.) on the SPR sensor slides was performed by ﬁrst
treating conﬂuent cell layers in cell culture ﬂasks with trypsin
in DPBS after which the cells were resuspended in the cell
culture medium. The SPR sensor slide was then placed in a cell
culturing polystyrene Petri dish with a cell growth area of 8.8
cm2 and 2 mL of the cell suspension was pipetted on the SPR
sensor slide. The optimum seeding density for culturing the
HT-29 cells on the SPR sensor slides was ∼1 × 104 cells/Petri
dish. The cells were allowed to grow on the SPR sensor slides
until they reached 90−100% conﬂuence.
2.4.2. SPR Measurements. The interaction between non-
coated and chitosan, WGA-, and GE11-coated C-PLGA NPs
and immobilized HT-29 cells at 37 °C were monitored by
using a Multi-Parametric SPR instrument (MP-SPR Navi 200,
BioNavis Ltd, Tampere, Finland) equipped with a single ﬂow
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channel with two detection spots. The signal responses in the
SPR measurements were recorded simultaneously with a laser
wavelength of 785 nm in two diﬀerent positions in the ﬂow
channel (upper and lower ﬂow channel positions) on the same
sensor covered with a cell monolayer. The NP sample
solutions for SPR measurements were prepared by diluting
the H2O-based stock formulations to a ﬁnal concentration of 1
mg/mL of the corresponding C-PLGA NP formulation with
the running medium (DMEM supplemented with 10 mM
HEPES, pH: 7.4), just before performing each SPR experi-
ment. The baseline for the SPR measurements was measured
for ∼60 min by ﬂowing the running medium through the SPR
ﬂow channel at a constant ﬂow rate of 10 μL/min. After the
baseline signal was stabilized, the sample solution was injected
into the SPR ﬂow channel by replacing the running medium
with the sample solution. The interaction of the NP
formulations with HT-29 cells were monitored at a constant
ﬂow speed of 10 μL/min by recording the full SPR spectra
between 60 and 78° every 3 s for up to 90 min. Because the full
SPR angular spectrum was recorded, the bulk eﬀect caused by
the diﬀerence in the refractive index of the DMEM running
buﬀer and the samples (i.e., diluted H2O-based stock solutions
of the NPs in DMEM) was compensated for by subtracting the
contribution of the total internal reﬂection angle (TIR;
sensitive for bulk refractive index changes) from the overall
change in the main SPR peak angular position (SPR PAP).
The corrected SPR responses were then used for further
analysis. Light microscope images (Leica DM IL LED
microscope with 5× and 10× magniﬁcations) of the HT-29
cell monolayers were taken immediately before and after each
SPR experiment in order to evaluate the integrity of the cell
monolayer.
2.5. In vitro Cell Studies with Noncoated and Coated
C-PLGA NPs. 2.5.1. Cell Culture and Cell Preparation.
Human Caucasian colon adenocarcinoma (HT-29) obtained
from the European Collection of Authenticated Cell Cultures
(ECACC) were cultured in a McCoy’s 5A medium
supplemented with 10% FBS at a density of about 2 × 106
cells/mL in a 75 cm2 culture ﬂask. The cells were maintained
at 37 °C, 95% relative humidity, and 5% CO2. The cells were
harvested weekly from plastic ﬂasks (75 cm2) with TrypLE
Express and the medium was changed twice per week.
2.5.2. Cellular Drug Uptake Assay. HT-29 cells were
cultured in a 12-well plate with a cell density of 1 × 104 cells/
per well and incubated in a 5% CO2 incubator at 37 °C for 24
h before cellular drug uptake studies. The cell association assay
was carried out at 37 °C in OPTI-MED-reduced serum
medium containing enough pure curcumin or the noncoated
or coated C-PLGA NP formulations so that each well
contained the same absolute amount of 200 μg curcumin.
Washing the wells with ice-cold PBS three times terminated
incubation of the cells with pure curcumin or the NPs. The
washed cells were lysed in PBS containing 0.5% Triton X-100,
then vortexed for 3 min followed by centrifugation of the cell
lysate for 10 min at 1200g to remove insoluble materials. The
supernatant was transferred to another tube and the amount of
curcumin was determined by diluting the supernatant with a
mobile phase mixture (composed of (A) 38% acetonitrile and
(B) 62% of a 0.05% phosphoric acid solution) and measured
with an AcquityTM ultraperformance liquid chromatography
instrument at λmax = 426 nm (Waters Corp., Milford,
Massachusetts, USA).
2.5.3. In Vitro Cytotoxicity of Noncoated and Coated C-
PLGA NPs. Cytotoxicity assays were performed by incubating
HT-29 cancer cell lines with curcumin in solution, noncoated
and chitosan, WGA- and GE11-coated C- PLGA NPs. Cells
were treated with the same absolute amount of curcumin (200
μg). HT-29 cells were seeded in 96-well plates and after the
attachment of cells; the plates were washed twice with 100 μL
of PBS. After washing, the sample solutions were added to the
wells. The wells were then incubated for 2 h. After incubation,
the samples were removed by pipetting and 10 μL of MTT
solution was added to each well. The plates were further
incubated for 3 h and the MTT solution was removed. The
blue crystals formed in each well were dissolved with 200 μL of
DMSO. Absorbance values from the wells were measured at
550 nm with a Multiscan GO Microplate Spectrophotometer
(ThermoFischer Scientiﬁc, Finland). Cell viability was
calculated based on the absorbance values.
2.6. In Vivo Experiments and Optical Imaging.
2.6.1. Mice. Six to eight week old female BALB/c mice were
obtained from and housed in the IOV-IRCCS Speciﬁc
Pathogen Free (SPF) animal facility. Procedures involving
animals and their care were in conformity with institutional
guidelines (D.L. 26/2014, and subsequent implementing
circulars), and the experimental protocol was approved by
the local “Organismo Preposto al Benessere Animale” (OPBA)
of Padua University, and authorized by the Italian Ministry of
Health (Authorization n.1050/2015-PR).
2.6.2. In Vivo Biodistribution of Noncoated and Ligand
Coated C-PLGA NPs. The noncoated and coated C-PLGA NPs
were labeled with a near-IR dye, that is Cy5.5, by using Cy5.5-
PEG-NH2. The labeling of the NPs was carried out by using a
similar two-step EDC/NHS method as described for WGA
lectin or GE11 peptide functionalization of the C-PLGA NPs,
as described in Section 2.2.3. In vivo optical imaging studies
were conducted to evaluate the biodistribution of the labeled
NPs in the GIT of mice. BALB/c mice were placed on a low-
manganese diet to reduce autoﬂuorescence from normal
mouse chow. Five days later, animals were randomly divided
into three groups of four animals each, and treated with Cy5.5-
coated noncoated C-PLGA, WGA-C-PLGA, and GE11-C-
PLGA NPs. The Cy5.5-labeled NP formulations were
administered by oral gavage in a total volume of 200 μL.
The in vivo total body scanning was performed at diﬀerent
time points using an Explore Optix instrument (ART,
Advanced Research Technologies, Montreal, Canada) by
setting the excitation pulsing laser at 650 nm and recording
the emission at 710 nm, thus performing a time course
scanning of animals (spatial resolution/scan step ﬁxed at 1.5
mm, exposure time 0.1 s, and laser power automatically
adjusted for each scan session). At 0, 1, 2, 4, 6, 24, and 48 h the
animals were anesthetized with a continuous ﬂow of 5%
isoﬂurane/oxygen mixture and placed inside a 37 °C heated
camera box and a longitudinal whole body ﬂuorescence image
was recorded. Before imaging, the anesthesia was maintained
using a nose cone delivery system for the duration of image
acquisition. One mouse from each group was imaged at 2 h
post administration and then sacriﬁced, and the abdominal
cavity was opened to visualize the GIT at place. Thereafter, the
entire GIT was removed and imaged alone, followed by
imaging of the carcass.
2.7. Statistical Analysis. Results are expressed as a mean
± standard deviation (SD). Statistical analyses were performed
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by using ANOVA followed by Tukey’s test. A diﬀerence at P <
0.05 was considered to be signiﬁcant.
3. RESULTS AND DISCUSSIONS
3.1. Preparation and Biopharmaceutical Character-
ization of Curcumin-Loaded PLGA NPs. 3.1.1. NP
Preparation. Curcumin-loaded PLGA NPs (C-PLGA NPs)
were coated with chitosan (CS), WGA or GE11 peptide
(GE11) for selective or targeted uptake of the NPs to HT-29
colon cancer cells in order to improve the delivery of curcumin
to the cells.
CS, a polycationic mucoadhesive polysaccharide, was
adsorbed on the negatively charged C-PLGA NP surface by
coulombic interaction. The NP decoration was carried out by
using 0.25, 0.50, and 1% CS solutions that yielded diﬀerent CS
densities on the NP surface, that is, 0.25% CS-C-PLGA, 0.50%
CS-C-PLGA, and 1% CS-C-PLGA NPs, respectively. WGA, a
mucoadhesive glycoprotein, was chemically anchored to the
carboxyl groups on the C-PLGA NP surface through a
condensation process to yield WGA-C-PLGA NPs coated with
33.0 ± 1.4 μg WGA/mg C-PLGA. NPs targeting colorectal
cancer cells (GE11-C-PLGA NPs) were obtained through
chemical conjugation of GE1144 peptide to C-PLGA NPs
which resulted in 38.1 ± 1.0 μg GE11 peptide/mg C-PLGA.
The degree of NP functionalization calculated based on the C-
PLGA NP size (220 ± 2 nm) and the PLGA NP density (1.2
mg/cm3)45 was found to correspond to a mean of 3.7 WGA
molecules/NP and 82 GE11 peptides/NP. The coupling
eﬃciency of WGA and the GE11 peptide ligand was calculated
by using eq 2 and was 74.5% and 82.7%, respectively.
3.1.2. Physicochemical Characterization of Noncoated
and Coated C-PLGA NPs. The dynamic light scattering (DLS)
data reported in Table 1 show that the CS coating signiﬁcantly
increased the size of the noncoated C-PLGA NPs, while the
PDI remained constant. The high negative zeta potential of the
noncoated C-PLGA NPs originates from the presence of a high
density of terminal carboxyl groups of PLGA. Coating the C-
PLGA NPs with CS solutions with diﬀerent polysaccharide
concentrations (i.e., 0.25, 0.5 and 1%) yielded NPs with similar
particle sizes and PDIs, while the zeta potential values
increased with increasing CS concentration. Thus, the use of
increasing CS concentrations for coating C-PLGA NPs
obviously resulted in an increased CS deposition on the NP
surface. The 1% CS-C-PLGA NPs exhibited a signiﬁcantly
higher positive zeta potential compared to the other CS-coated
NPs, which could result in high mucoadhesive properties. The
WGA and GE11 decoration did not substantially aﬀect the size
of the coated C-PLGA NPs probably because of the limited
number of protein and peptide molecules conjugated on the
particle surfaces. However, WGA and GE11 conjugation
reduced the absolute value of the negative zeta-potential of
the NPs, but the particles still maintained a negative zeta
potential. The slight quenching of the negative zeta potential
obtained by WGA and GE11 conjugation can be attributed to
the limited number of carboxyl groups engaged in the protein
conjugation and to the overall positive charge of these
polypeptidic molecules with isoelectric points of 9 and 9.76,
respectively. In this regard, it is interesting to note that in the
case of WGA-C-PLGA NPs bearing only ∼4 lectin molecules/
NP, the zeta potential is highly negative −20.5 mV, while in
the case of GE11-C-PLGA NPs bearing about 82 peptide
molecules/NP the zeta potential was −10.8 mV. These results
indicate that the noncoated C-PLGA NPs were successfully
modiﬁed with both ligands.
The TEM images reported in Figure 1 show that all NPs had
regular spherical shapes indicating that the surface coating did
not inﬂuence the particle morphology. The slightly smaller size
(i.e., <200 nm) observed by TEM compared to DLS is in
agreement with the dry state of NPs, while DLS provides the
hydrodynamic diameter of NPs. Table 1 shows that the
noncoated C-PLGA NPs have a high curcumin encapsulation
eﬃciency (EE 74%). The encapsulation eﬃciency of the
coated NPs was slightly lower compared to the noncoated C-
PLGA NPs which may be ascribed to partial curcumin release
during the coating process.14,38,39
3.1.3. In Vitro Drug Release. Curcumin release was assessed
by NP incubation in three diﬀerent pH release media
simulating: gastric ﬂuid (SGF), small intestine ﬂuid (SIF),
and colon ﬂuid (SCF) (Figure S1). The sequential incubation
of noncoated C-PLGA NPs in SGF (1−2 h in Figure S1) and
SIF (3−5 h in Figure S1) yielded a 10% curcumin release
within 5 h (Figure S1). Hereafter, when the noncoated C-
PLGA NPs were incubated in SIF media a biphasic proﬁle with
a burst release with 56% of curcumin released within the ﬁrst
Table 1. Particle Size, Size Distribution, Zeta Potential, and Encapsulation Eﬃciency of Noncoated and Coated Curcumin-
Loaded PLGA NPs (Mean ± SD, n = 3)
formula particle size [nm] PDI ζ-potential [mV] encapsulation eﬃciency (EE %)
C-PLGA 220 ± 2 0.186 ± 0.023 −36.8 ± 0.0 74 ± 4
CS-C-PLGA 0.25% 245 ± 4 0.172 ± 0.024 2.5 ± 2.1 64 ± 2
0.50% 251 ± 3 0.276 ± 0.002 4.8 ± 1.2 62 ± 1
1% 252 ± 3 0.126 ± 0.033 32.9 ± 1.7 54 ± 2
WGA-C-PLGA 227 ± 3 0.195 ± 0.011 −20.5 ± 0.8 66 ± 1
GE11-C-PLGA 209 ± 2 0.140 ± 0.044 −10.8 ± 0.9 62 ± 2
Figure 1. TEM images of noncoated and coated C-PLGA NPs (scale
bar 200 nm). (A) Noncoated C-PLGA NPs, (B) 1% CS-C-P-PLGA
NPs, (C) WGA-C-PLGA NPs, and (D) GE11-C-PLGA NPs.
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24 h was followed by a slow release over a period of 48 h
yielding a ﬁnal curcumin release of 78% (6−24 h in Figure S1).
These results are in agreement with the higher curcumin
solubility at pH 7.4 with respect to acidic conditions.46
Noncoated C-PLGA, WGA-C-PLGA, and GE11-C-PLGA
NPs showed similar curcumin release proﬁles, suggesting that
the surface modiﬁcation of C-PLGA NPs with a few protein or
peptide molecules does not remarkably aﬀect the drug release
properties of the formulation. In SCF during the ﬁrst burst
phase, the WGA-C-PLGA and GE11-C-PLGA NPs released
about 62 and 54% of the loaded drug, respectively. Then, the
release slowly continued up to 76% for WGA-C-PLGA and
84% for GE11-C-PLGA NPs in 48 h. The CS coating had a
stronger eﬀect on the drug release from the NPs compared to
WGA and GE11. The 1% CS-C-PLGA NPs showed in fact a
slower curcumin release compared to the other formulations:
about 42 and 58% of the loaded curcumin was released in 24 h
and in 48 h, respectively. The slower release observed after CS
coating may be because of the CS layer on the NP surface that
represents a barrier to the diﬀusion of curcumin.47
Furthermore, the aﬃnity of curcumin for CS may also reduce
the drug availability.
The kinetic data obtained by the elaboration of the in vitro
release proﬁles (Table S1) show that the curcumin release
from all the C-PLGA NPs ﬁts the Higuchi diﬀusion model,48,49
which is in agreement with the fact that degradation of PLGA
can last from weeks to months.50
3.1.4. In Vitro Adsorption of Crude PM. The mucoadhesive
properties of the NP formulations were evaluated by
adsorption of PM on the surface of C-PLGA, 0.25, 0.5, and
1% CS-C-PLGA, WGA-C-PLGA, and GE11-C-PLGA NPs.
The noncoated C-PLGA NPs adsorbed 22.29% of PM after 2 h
incubation at 37 °C (Figure S2). According to its well-known
mucoadhesivity, chitosan-coated NPs showed high PM
adsorption, which was 3.0, 3.2, and 3.4-fold compared to C-
PLGA NPs in the case of 0.25, 0.50, and 1% CS-C-PLGA NPs,
respectively. These results indicate that in this coating range
the density of chitosan and the positive charge on the NP
surface has a limited eﬀect on their ﬁnal mucoadhesivity. This
may be due to a surface saturation by PM even at low chitosan
density.51 PM adsorption on WGA-C-PLGA was 2.3-fold
compared to the noncoated C-PLGA NPs, indicating that a
limited amount of this protein has a remarkable eﬀect on
mucoadhesion properties of the NPs. The PM interaction with
WGA-C-PLGA NPs is attributed to speciﬁc binding with the
N-acetyl-D-glucosamine and sialic acid residues of PM
glycoproteins.52 Unexpectedly, also GE11, a nonmucoadhesive
peptide, was found to increase the PM adsorption on the NPs
of about 2-fold. The GE11-C-PLGA NPs/PM association
probably occurs through nonspeciﬁc coulombic GE11/mucin
interactions.
3.1.5. In Vitro Stability of Diﬀerent C-PLGA NPs. Stability
studies of the C-PLGA NPs were carried out by storing the
NPs in high purity water at RT and 4 °C for up to 4 months.
Table S2 shows that the particle size and PDI of noncoated C-
PLGA, 1% CS-C-PLGA, WGA-C-PLGA, and GE11-C-PLGA
NPs did not change over time indicating that the NPs have a
good long-term stability. On the contrary, the 0.25 and 0.50%
CS-C-PLGA NPs showed a signiﬁcant size and PDI increase
after 1 month storage. The lower stability of 0.25 and 0.5% CS-
PLGA NPs compared to the other NPs can be attributed to the
low zeta potential (+2.5 and +4.5 mV, respectively, Table 1).
According to these results, the 1% CS-C-PLGA, WGA-C-
PLGA, and GE11-C-PLGA NPs were chosen for further
studies.
In view of oral delivery, the colloidal stability of the NPs was
also investigated by incubating noncoated C-PLGA, 1% CS-C-
PLGA, WGA-C-PLGA, and GE11-C-PLGA NPs at 37 °C for
up to 2 h in SGF, up to 6 h in SIF, and up to 24 h in SCF to
simulate GI-tract residence times. All NPs except 1% CS-C-
PLGA NPs were stable in the three ﬂuids without relevant
particle size and PDI changes (Table S3). The size increase of
1% CS-C-PLGA NPs in SGF may be due to a change of the
hydrophilic/hydrophobic surface balance that results in a more
hydrophobic surface. This hypothesis seems to be conﬁrmed
by the high stability observed when the 1% CS-C-PLGA NPs
were incubated in SIF, which contains the bile acid
taurocholate that apparently stabilizes the 1% CS-C-PLGA
NPs because of its surfactant properties.
3.2. Interaction of Diﬀerent C-PLGA NPs with
Biomembranes and Cells. 3.2.1. QCM Analyses with
Supported Lipid Bilayer. The interaction of noncoated C-
PLGA, 1% CS-C-PLGA, WGA-C-PLGA, and GE11-C-PLGA
NPs with cell model membranes were investigated by using the
QCM technique in combination with SLBs composed of a
simple two-component phospholipid mixture (DOPC/DOPS,
75/25 mol %) or a mixture of HT-29 cell membrane extract
and EggPC. DOPC/DOPS SLBs were used to mimic the
negative charge of natural cell membranes. The HT-29 cell
membrane extract incorporated into the EggPC SLB was used
to evaluate the interaction of NPs with biological targets. The
DOPC/DOPS and the HT-29 cell membrane extract/EggPC
vesicle mixtures were spread on the silica-coated QCM sensor
to form the SLBs according to standard protocols reported in
the literature.29,30
Figure 2 shows the adsorption-bursting behavior typically
observed in QCM responses during vesicle spreading when
SLBs are formed. Table 2 reports the size and zeta potential of
the vesicles used to form the SLBs, as well as the equilibrium
frequency change, Δf, for the SLB. The size of the vesicles
obtained with the HT-29 cell membrane extract/EggPC
resembled the size of plain EggPC vesicles, while the zeta
potential was close to the average of the components. This
result suggests that the HT-29 cell membrane extract
Figure 2. QCM signal responses for the pure HT-29 cell membrane
extract, and SLB formation through vesicle spreading of EggPC
vesicles, HT-29 cell membrane extract/EggPC (1/1 mass ratio)
vesicles and DOPC/DOPS (75/25 mol %) vesicles. Arrows indicate
time of injection of vesicles. Each QCM signal response correspond to
a separate measurement and have been shifted in time for clarity.
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components and EggPC are incorporated in the hybrid
vesicles. The equilibrium frequency values obtained with the
SLBs in this study are well in line with the values of typical
SLBs reported in the literature.30
Figure 3 shows the changes in QCM frequency and
dissipation at the 3rd overtone during the interaction of
various NPs with DOPC/DOPS SLBs. The NPs were injected
over the SLBs at time t = 0. After 30 min, buﬀer was injected to
rinse the system and clear out the NPs that did not interact
with the SLBs (vertical dashed line). The frequency and
dissipation changes indicate the extent and the type of the NP
interaction with the SLBs. The QCM measurements show that
the various NPs underwent similar reversible interaction with
the DOPC/DOPS SLBs, except for the 1% CS-C-PLGA NPs
that showed a slightly higher dissipation change during sample
injection compared to the other NPs. Additionally, the
frequency and dissipation signals in the case of 1% CS-C-
PLGA NPs do not return to the starting level when ﬂushing
with running buﬀer, as observed with the other NPs. This is
probably a consequence of electrostatic interactions between
the highly positively charged 1% CS-C-PLGA NPs (zeta
potential ≈ +33 mV) and the negatively charged DOPC/
DOPS SLB (∼−27 mV).
In the case of the HT-29 cell membrane extract/EggPC
SLBs the small frequency (∼3 Hz) and dissipation (∼1 ×
10−6) changes at the 3rd overtone during the interaction of the
noncoated C-PLGA NPs reported in Figure 4 indicate that
NP/SLB interactions occurs according to weak associations.
The 1% CS-C-PLGA, WGA-C-PLGA, and GE11-C-PLGA
NPs showed higher frequency changes (40, 40, and 15 Hz,
respectively) and dissipation changes (25 × 10−6, 20 × 10−6
and 10 × 10−6, respectively) compared to noncoated C-PLGA
NPs (Figure 4). The 1% CS-C-PLGA displayed the highest
QCM responses corresponding to over 10 times higher signal
responses compared to the ones obtained with noncoated C-
PLGA NPs. This strong adsorption of 1% CS-C-PLGA NPs on
the HT-29 cell membrane extract/EggPC SLBs can be ascribed
to nonspeciﬁc electrostatic interactions between the negatively
charged SLBs and the positively charged NPs. Interestingly, the
Table 2. Vesicle Size and ζ-Potential of Vesicles Used for
SLB Formationa
SLB composition
vesicle size
(nm)
ζ-potential
(mV) Δf 3 (Hz)
DOPC/DOPS
(75/25 mol %)
71.5 ± 1.3 −27.6 ± 1.3 −27.3 ± 1.4
pure EggPC 100.7 ± 1.0 −3.7 ± 0.1 −28.0 ± 3.2
pure HT-29 membrane
extract
224.5 ± 4.6 −15.5 ± 1.7
HT-29 membrane
extract/EggPC
(1/1 mass ratio)
109.9 ± 2.6 −8.5 ± 0.1 −27.5 ± 4.9
aEquilibrium frequency change, normalized Δf 3, for the ﬁnal SLB of
the DOPC/DOPS (75/25 mol %) mixture, pure EggPC and the
mixture of membrane extract/EggPC (1/1 mass ratio). Mean ± SD, n
= 3.
Figure 3. (A) Normalized QCM frequency changes at the 3rd
overtone and (B) dissipation changes at the 3rd overtone during
interaction of noncoated and coated C-PLGA NPs with a DOPC/
DOPS (75:25 mol %) SLB. Arrows indicate time point for injection of
diﬀerent PLGA NPs and the vertical dashed line indicates the time
point for ﬂushing with the running buﬀer.
Figure 4. (A) Normalized QCM frequency changes and (B)
dissipation changes of the 3rd overtone for diﬀerent C-PLGA NPs
during the interaction with an SLB composed of the HT-29
membrane extract/EggPC (1:1 mass ratio). Arrows indicate time
point for injection of the diﬀerent PLGA NPs and the vertical dashed
line indicates the time point for ﬂushing with the running buﬀer.
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QCM responses obtained with WGA-C-PLGA NPs were
similar to those obtained with 1% CS-C-PLGA NPs despite the
fact that the former possessed a highly negative surface charge.
The GE11-C-PLGA NPs induced lower QCM responses
compared to 1% CS-C-PLGA and WGA-C-PLGA NPs, but
still signiﬁcantly higher (over 5 times higher) compared to the
noncoated C-PLGA NPs. Because both WGA-C-PLGA and
GE11-C-PLGA NPs are negatively charged, the NP adsorption
on these SLBs occurs through speciﬁc binding. The WGA-C-
PLGA NPs can speciﬁcally interact with glycoproteins and
-lipids on the cell membrane surface, namely, N-acetyl-D-
glucosamine and N-acetyl-D-neuraminic acid residues, and
GE11-C-PLGA NPs interact with the HT-29 cell receptors.
The weaker interaction of GE11-C-PLGA NPs compared to
WGA-C-PLGA NPs could be ascribed to a diﬀerence in
density of the receptors for the two targeting agents on the
HT-29 cell membrane extract/EggPC SLB or diﬀerent binding
aﬃnities.
3.2.2. SPR Analyses with HT-29 Cell Monolayers. In order
to elucidate the mechanism of the NP interaction with living
cells, SPR measurements were carried out with conﬂuent colon
cancer HT-29 cell monolayers. The immobilization of HT-29
cell monolayers on the SPR sensors was validated before each
interaction measurement by measuring the full SPR angular
spectrum of the cell monolayer. Figure 5A shows that the main
SPR PAP and the shape of the TIR region of the full SPR
angular spectrum when the HT-29 cell monolayer is
immobilized are substantially shifted to higher angles with
respect to the spectrum obtained with a pure gold-coated SPR
sensor (from ∼66° to ∼69°). A SPR PAP at about 69° and the
smooth shape of the TIR area conﬁrmed the conﬂuence of the
HT-29 cell layer.34,35,53 The HT-29 cell monolayer conﬂuence
on the SPR sensors was also conﬁrmed by optical microscopy.
The microscopy images reported in Figure 5B,C show the cell
conﬂuence and cell integrity without changes in the
morphology after SPR measurements.
The SPR signals obtained during the injection of pure
curcumin solution reported in Figure S3A show an initial
negative shift followed by a leveling out and slow increase of
the SPR PAP. The noncoated and coated C-PLGA NPs
showed also an initial negative shift with a minimum SPR PAP
signal in the range of 3−10 min followed by an increase (>10
min) (Figure S3B−E). Initial negative shifts were observed in
the TIR angular position as well (Figure S3). In contrast to the
SPR PAP, the TIR angular position remained constant after
the initial negative shift. This can be attributed to the fact that
the TIR angular position is only sensitive to changes in bulk
refractive indexes, while the SPR PAP is sensitive to refractive
index changes in the close vicinity of the sensor surface. Thus,
the initial negative decrease of the SPR responses can be
attributed to optical diﬀerences (i.e., diﬀerent refractive
indexes) between the running buﬀer (DMEM supplemented
with 10 mM HEPES, pH 7.4) and the injected sample
solutions, which were actually formulations in aqueous
medium diluted in the running buﬀer. The initial decrease in
both SPR signals is due to an increase of water content in the
samples because water has a lower refractive index than the
running buﬀer. However, the increase in the SPR PAP
Figure 5. (A) Full SPR angular spectra of a pure gold-coated SPR sensor (dashed black line) and a conﬂuent HT-29 cell monolayer-covered SPR
sensor (solid blue line). The large shift in the SPR PAP and the TIR region to higher angles, and the smoother shape in the TIR region conﬁrms
the presence of a conﬂuent cell monolayer. (B) Optical microscope image of a conﬂuent HT-29 cell monolayer on a gold-coated SPR sensor. (C)
Optical microscope image of the HT-29 cell monolayer after an SPR interaction measurement demonstrating the preserved cell monolayer
integrity.
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responses after the initial decrease, which is not seen in the
TIR angular position responses, can be attributed to NP-cell
surface interactions and NP-cell uptake.
The TIR angular position responses were subtracted from
the corresponding SPR PAP responses to evaluate the targeting
and cell uptake events of the curcumin formulations (Figure
S3). This removed any contribution of optical diﬀerences
between the curcumin formulations and the running buﬀer,
and provided an SPR response that only reﬂects the targeting
and cell uptake events of the diﬀerent curcumin formulations.
Figure 6A shows that the interaction kinetics of the NPs
obtained by the TIR-subtracted SPR responses measured in
the lower position of the ﬂow channel are in good agreement
with the results obtained by the QCM combined with the HT-
29 cell membrane extract/EggPC SLB analysis. The targeting
and cell uptake of the various NPs could then be estimated by
integrating the area under the TIR-subtracted SPR responses
reported in Figure 6B. The integrated areas show that the HT-
29 cell interaction and internalization of 1% CS-C-PLGA,
WGA-C-PLGA, and GE11-C-PLGA NPs are clearly higher
compared to those obtained with curcumin in solution and
noncoated C-PLGA NPs.
3.2.3. In Vitro Cell Uptake and Cytotoxicity Studies. In
order to corroborate the real-time label-free QCM and SPR
results, in vitro cell uptake and cytotoxicity assays were
performed using HT-29 human colorectal adenocarcinoma
cells. Figure 7A shows the HT-29 cell uptake of curcumin after
2 h incubation. The cell uptake of curcumin in solution was 3.7
± 0.6 μg/104 cells, while the curcumin uptake from noncoated
C-PLGA, 1% CS-C-PLGA, WGA-C-PLGA, and GE11-C-
PLGA NPs was 7.0 ± 0.3, 13.5 ± 1.0, 26.0 ± 1.3, and 27.3 ±
4.9 μg/104 cells, respectively. These results are in good
agreement with the cell interaction data obtained by QCM and
SPR analysis reported above, and demonstrate that the
selective NP interaction achieved with WGA-C-PLGA and
GE11-C-PLGA is much more eﬃcient than nonselective cell
interaction obtained with 1% CS-C-PLGA. It should be noted
that CS is a highly positively charged mucoadhesive material.
Consequently, the interactions of 1% CS-C-PLGA NPs with
mucin (Figure S2) and the HT-29 membrane extract/EggPC
SLB are primarily electrostatic in nature (Figure 4). However,
the interaction of 1% CS-C-PLGA NPs with HT-29 cells
measured by SPR was lower compared to WGA-C-PLGA and
GE11-C-PLGA NPs (Figure 6). Furthermore, the nonselective
interaction of 1% CS-C-PLGA NPs with cells may result in a
diﬀerent cell-uptake mechanism compared to the targeted NPs,
which consequently could lead to diﬀerences in the intra-
cellular delivery of curcumin. Accordingly, the 1% CS-C-PLGA
NPs were less eﬃcient in the intracellular delivery compared to
WGA-C-PLGA and GE11-C-PLGA NPs.
The cytotoxicity results reported in Figure 7B are in
agreement with the cell uptake results shown in Figure 7A and
Figure 6. (A) TIR-subtracted SPR response during the interaction of
pure curcumin solution and diﬀerent C-PLGA NPs with HT-29 cells
(measured in the lower ﬂow channel position of the cell covered
sensor). Arrow indicates time point for injection of the diﬀerent
PLGA NPs. (B) Integrated area under the TIR-subtracted SPR
response curve for pure curcumin solution and diﬀerent C-PLGA NPs
measured on two separate positions (lower and upper ﬂow channel
positions) on the same sensor with conﬂuent HT-29 cell monolayers.
SPR measurements with each formulation were performed on
diﬀerent HT-29 cell-covered SPR sensors.
Figure 7. (A) In vitro cell uptake of curcumin and (B) cell viability
after 2 h incubation with pure curcumin solution, noncoated C-
PLGA, and coated C-PLGA NPs with HT-29 colorectal adenocarci-
noma cells (mean ± SD, n = 3). Not signiﬁcant (N.S.), * signiﬁcant
diﬀerence at the 0.05 level.
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conﬁrm that curcumin is indeed released from the NPs. After 2
h, incubation with curcumin in solution or formulated with
noncoated C-PLGA, 1% CS-C-PLGA, WGA-C-PLGA, and
GE11-C-PLGA NPs, the HT-29 cell viability was 83 ± 16, 96
± 11, 79 ± 11, 62 ± 8, and 43 ± 13%, respectively. It is worth
noting that the active targeting obtained with WGA-C-PLGA
and GE11-C-PLGA NPs yields the highest cytotoxicity with a
signiﬁcant diﬀerence compared to the noncoated C-PLGA
NPs.
Importantly, the QCM data (Figure 4) are in fair agreement
with the cell uptake and cytotoxicity results obtained by NP
incubation with HT-29 cells, demonstrating that this
sophisticated technique can be properly exploited to obtain
relevant information about the cell-targeting capability of
colloidal drug delivery systems. Also, the SPR results (Figure
6) are in very good agreement with the higher curcumin
uptake obtained by traditional in vitro cell uptake assay.
3.3. In Vivo Delivery of Noncoated and Targeted C-
PLGA NPs. A preliminary in vivo comparative delivery study
was carried out to verify that the targeted C-PLGA NPs with
colon-selective agents, namely WGA and GE11, could
withstand other GI tract conditions before reaching the
colon, and to conﬁrm their colon selectivity of these NPs.
The study was performed by oral administration to mice of
Cy5.5 labeled noncoated C-PLGA, WGA-C-PLGA, and GE11-
C-PLGA NPs. The images reported in Figure 8 show that all
NPs partially remained in the stomach up to 6 h from
administration. However, noncoated C-PLGA and GE11-C-
PLGA NPs were cleared out without deposition in the colon
while high ﬂuorescence signal corresponding to WGA-C-
PLGA NPs was found in the colon, indicating that these NPs
adsorb to this GI tract. These results are in fair agreement with
the cell aﬃnity of the NPs discussed above. WGA-C-PLGA
NPs can in fact recognize the glycoproteins and glycolipids of
the normal cells of colon. On the contrary, neither the
noncoated C-PLGA nor the GE11-PLGA NPs have a speciﬁc
target in the colon of healthy mice, and consequently they did
not deposit in this GI tract as observed by the images reported
in Figure 8.
4. CONCLUSIONS
Curcumin-loaded PLGA NPs were successfully prepared and
coated with chitosan, WGA and GE11 to yield drug carriers for
ameliorating curcumin delivery to HT-29 colon cancer cells.
The properties of the coated C-PLGA NPs were comparatively
investigated by standard in vitro physicochemical techniques.
Stability studies revealed a good colloidal stability of the coated
C-PLGA NPs formulations in synthetic gastrointestinal ﬂuids.
The NP interactions and cell uptake were studied by means of
innovative investigational techniques, namely, QCM combined
with SLBs and SPR combined with living cells. The QCM and
SPR techniques in combination with biomimetic sensing layers
were found to be successful tools to investigate the targeting
properties of NPs. These innovative techniques allowed in fact
for elucidating a few aspects of NP/cell interactions and uptake
providing for the correlation between the nature of the coating
and the cell selectivity. The results showed that CS-coated C-
PLGA NPs can interact with the cells by nonspeciﬁc
electrostatic mechanisms, while WGA- and GE11-coated C-
PLGA NPs mediate active recognition of speciﬁc cell targets.
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Figure 8. In vivo optical images of mice orally administered with (A) noncoated C-PLGA, (B) WGA-C-PLGA and (C) GE11-C-PLGA NPs
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additional mouse from each group was imaged at 2 h post administration and then sacriﬁced, to expose and visualize the GIT at place for
ﬂuorescent NP detection. Thereafter, the entire GIT was removed and imaged alone, followed by imaging of the remaining carcass (right panels).
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